 Shanlee Davis
Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Klinefelter Syndrome | 16 | 2025 | 65 | 6.690 |
Why?
| | Turner Syndrome | 9 | 2024 | 54 | 4.470 |
Why?
| | Trisomy | 4 | 2025 | 80 | 2.760 |
Why?
| | Sex Chromosome Aberrations | 9 | 2025 | 64 | 2.600 |
Why?
| | Sex Chromosome Disorders | 3 | 2025 | 23 | 2.420 |
Why?
| | Testosterone | 6 | 2025 | 409 | 2.080 |
Why?
| | XYY Karyotype | 4 | 2025 | 22 | 1.900 |
Why?
| | Neurodevelopmental Disorders | 2 | 2025 | 181 | 1.550 |
Why?
| | Chromosomes, Human, X | 5 | 2025 | 73 | 1.380 |
Why?
| | Mosaicism | 4 | 2024 | 73 | 1.340 |
Why?
| | Oxandrolone | 3 | 2018 | 8 | 1.270 |
Why?
| | Child Development | 2 | 2025 | 475 | 1.140 |
Why?
| | Sex Chromosome Disorders of Sex Development | 3 | 2025 | 16 | 1.120 |
Why?
| | Cardiovascular Diseases | 5 | 2025 | 2111 | 0.980 |
Why?
| | Puberty | 4 | 2024 | 146 | 0.860 |
Why?
| | Anti-Mullerian Hormone | 2 | 2020 | 57 | 0.820 |
Why?
| | Body Composition | 4 | 2025 | 684 | 0.790 |
Why?
| | Registries | 4 | 2024 | 2035 | 0.730 |
Why?
| | Testis | 3 | 2018 | 151 | 0.720 |
Why?
| | Child | 27 | 2025 | 21935 | 0.710 |
Why?
| | Monosomy | 1 | 2021 | 12 | 0.710 |
Why?
| | Disorders of Sex Development | 1 | 2021 | 39 | 0.680 |
Why?
| | Sex Chromosomes | 4 | 2025 | 50 | 0.680 |
Why?
| | Inhibins | 1 | 2020 | 44 | 0.670 |
Why?
| | Ovarian Reserve | 1 | 2020 | 16 | 0.670 |
Why?
| | Dyslipidemias | 1 | 2022 | 176 | 0.660 |
Why?
| | Mitochondria, Muscle | 1 | 2021 | 116 | 0.660 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2020 | 38 | 0.660 |
Why?
| | Mental Disorders | 3 | 2025 | 1077 | 0.650 |
Why?
| | Metabolic Syndrome | 3 | 2020 | 354 | 0.640 |
Why?
| | Phenotype | 7 | 2025 | 3196 | 0.640 |
Why?
| | Androgens | 2 | 2018 | 187 | 0.640 |
Why?
| | Case-Control Studies | 6 | 2025 | 3556 | 0.590 |
Why?
| | Aneuploidy | 5 | 2024 | 89 | 0.550 |
Why?
| | Electronic Health Records | 3 | 2025 | 1069 | 0.550 |
Why?
| | Prevalence | 6 | 2025 | 2734 | 0.500 |
Why?
| | Adolescent | 20 | 2025 | 21513 | 0.500 |
Why?
| | Male | 31 | 2025 | 67762 | 0.490 |
Why?
| | Body Height | 1 | 2017 | 199 | 0.490 |
Why?
| | Infertility, Male | 1 | 2015 | 61 | 0.480 |
Why?
| | Humans | 43 | 2025 | 137585 | 0.470 |
Why?
| | Adipose Tissue | 1 | 2019 | 635 | 0.470 |
Why?
| | Female | 28 | 2025 | 73304 | 0.470 |
Why?
| | Hypokalemia | 1 | 2014 | 24 | 0.460 |
Why?
| | Adrenal Hyperplasia, Congenital | 2 | 2025 | 37 | 0.410 |
Why?
| | Hypertension | 1 | 2022 | 1295 | 0.400 |
Why?
| | Double-Blind Method | 4 | 2025 | 1993 | 0.390 |
Why?
| | Child, Preschool | 14 | 2025 | 11074 | 0.380 |
Why?
| | Veterans | 1 | 2024 | 1476 | 0.380 |
Why?
| | Diabetic Ketoacidosis | 1 | 2014 | 201 | 0.370 |
Why?
| | Diabetes Mellitus | 1 | 2020 | 1040 | 0.360 |
Why?
| | Muscle, Skeletal | 1 | 2021 | 1724 | 0.360 |
Why?
| | Obesity | 2 | 2022 | 2992 | 0.330 |
Why?
| | Infant, Newborn | 5 | 2025 | 6079 | 0.330 |
Why?
| | Cross-Sectional Studies | 7 | 2025 | 5472 | 0.330 |
Why?
| | Follow-Up Studies | 4 | 2025 | 5131 | 0.320 |
Why?
| | Infant | 7 | 2025 | 9465 | 0.300 |
Why?
| | Estradiol | 2 | 2023 | 521 | 0.290 |
Why?
| | Chromosomes, Human, Y | 2 | 2021 | 24 | 0.250 |
Why?
| | Epilepsy | 1 | 2010 | 333 | 0.250 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2010 | 413 | 0.240 |
Why?
| | Cohort Studies | 4 | 2025 | 5742 | 0.240 |
Why?
| | Morbidity | 2 | 2024 | 324 | 0.240 |
Why?
| | Karyotype | 2 | 2023 | 18 | 0.230 |
Why?
| | Biological Specimen Banks | 1 | 2025 | 102 | 0.230 |
Why?
| | Blood Glucose | 1 | 2014 | 2186 | 0.220 |
Why?
| | Meta-Analysis as Topic | 1 | 2025 | 186 | 0.220 |
Why?
| | United Kingdom | 1 | 2025 | 318 | 0.220 |
Why?
| | Psychotropic Drugs | 1 | 2025 | 68 | 0.220 |
Why?
| | Adult | 11 | 2025 | 37929 | 0.220 |
Why?
| | Y Chromosome | 1 | 2023 | 11 | 0.220 |
Why?
| | Young Adult | 8 | 2024 | 13209 | 0.210 |
Why?
| | Azabicyclo Compounds | 1 | 2022 | 6 | 0.190 |
Why?
| | Oxadiazoles | 1 | 2022 | 33 | 0.190 |
Why?
| | Receptors, Corticotropin-Releasing Hormone | 1 | 2022 | 29 | 0.190 |
Why?
| | Comorbidity | 2 | 2025 | 1622 | 0.180 |
Why?
| | Quality of Life | 2 | 2024 | 2892 | 0.180 |
Why?
| | Phosphocreatine | 1 | 2021 | 46 | 0.180 |
Why?
| | Adenosine Diphosphate | 1 | 2021 | 79 | 0.180 |
Why?
| | Body Mass Index | 2 | 2020 | 2389 | 0.180 |
Why?
| | Transgender Persons | 1 | 2024 | 186 | 0.170 |
Why?
| | Genitalia | 1 | 2021 | 30 | 0.170 |
Why?
| | Gonadotropins | 1 | 2020 | 40 | 0.170 |
Why?
| | Developmental Disabilities | 2 | 2016 | 263 | 0.160 |
Why?
| | Waist Circumference | 1 | 2020 | 143 | 0.160 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2021 | 317 | 0.160 |
Why?
| | Genetic Association Studies | 1 | 2021 | 377 | 0.160 |
Why?
| | Prognosis | 2 | 2019 | 4030 | 0.160 |
Why?
| | Hypogonadism | 1 | 2020 | 92 | 0.160 |
Why?
| | Magnetoencephalography | 1 | 2020 | 149 | 0.160 |
Why?
| | Inservice Training | 1 | 2020 | 116 | 0.160 |
Why?
| | Focal Dermal Hypoplasia | 1 | 2019 | 5 | 0.150 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2023 | 293 | 0.150 |
Why?
| | Failure to Thrive | 1 | 2019 | 29 | 0.150 |
Why?
| | Adenosine Triphosphate | 1 | 2021 | 491 | 0.150 |
Why?
| | Testicular Hormones | 1 | 2018 | 9 | 0.150 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2021 | 611 | 0.150 |
Why?
| | Face | 1 | 2020 | 173 | 0.150 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2020 | 197 | 0.150 |
Why?
| | Motor Skills Disorders | 1 | 2018 | 28 | 0.150 |
Why?
| | Genome-Wide Association Study | 1 | 2025 | 1431 | 0.150 |
Why?
| | Growth Disorders | 1 | 2019 | 86 | 0.150 |
Why?
| | Mentors | 1 | 2020 | 202 | 0.140 |
Why?
| | Triglycerides | 1 | 2020 | 524 | 0.140 |
Why?
| | Interprofessional Relations | 1 | 2020 | 283 | 0.140 |
Why?
| | Mentoring | 1 | 2020 | 149 | 0.140 |
Why?
| | Overweight | 1 | 2022 | 558 | 0.140 |
Why?
| | Eosinophilic Esophagitis | 1 | 2021 | 325 | 0.130 |
Why?
| | Patient Acceptance of Health Care | 1 | 2023 | 806 | 0.130 |
Why?
| | Heart Defects, Congenital | 1 | 2024 | 842 | 0.130 |
Why?
| | X Chromosome Inactivation | 1 | 2016 | 25 | 0.130 |
Why?
| | Speech Disorders | 1 | 2016 | 31 | 0.130 |
Why?
| | Truth Disclosure | 1 | 2016 | 48 | 0.130 |
Why?
| | Language Development Disorders | 1 | 2016 | 41 | 0.130 |
Why?
| | Risk | 1 | 2019 | 912 | 0.130 |
Why?
| | Imaging, Three-Dimensional | 1 | 2020 | 580 | 0.130 |
Why?
| | Delivery of Health Care | 1 | 2023 | 951 | 0.120 |
Why?
| | Algorithms | 1 | 2023 | 1704 | 0.120 |
Why?
| | Genetic Counseling | 1 | 2016 | 77 | 0.120 |
Why?
| | Research | 1 | 2019 | 451 | 0.120 |
Why?
| | Transcription Factors | 1 | 2023 | 1719 | 0.120 |
Why?
| | Body Weight | 1 | 2019 | 985 | 0.120 |
Why?
| | Child Behavior Disorders | 1 | 2016 | 144 | 0.110 |
Why?
| | Mitochondria | 1 | 2021 | 948 | 0.110 |
Why?
| | Child Behavior | 1 | 2017 | 248 | 0.110 |
Why?
| | Potassium | 1 | 2014 | 147 | 0.110 |
Why?
| | Muscle Strength | 1 | 2017 | 317 | 0.110 |
Why?
| | Sex Factors | 1 | 2019 | 2071 | 0.100 |
Why?
| | Polymorphism, Genetic | 1 | 2016 | 660 | 0.100 |
Why?
| | Severity of Illness Index | 3 | 2017 | 2828 | 0.100 |
Why?
| | Insulin Resistance | 1 | 2021 | 1208 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 1 | 2021 | 2426 | 0.100 |
Why?
| | Emergency Service, Hospital | 1 | 2024 | 2069 | 0.100 |
Why?
| | Longitudinal Studies | 1 | 2019 | 2844 | 0.090 |
Why?
| | Autism Spectrum Disorder | 1 | 2017 | 395 | 0.090 |
Why?
| | Hospitalization | 2 | 2024 | 2199 | 0.090 |
Why?
| | Hypoglycemia | 1 | 2016 | 445 | 0.090 |
Why?
| | Treatment Outcome | 3 | 2022 | 10811 | 0.080 |
Why?
| | United States | 2 | 2025 | 14841 | 0.080 |
Why?
| | Biomarkers | 2 | 2022 | 4149 | 0.080 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1774 | 0.080 |
Why?
| | Cognition | 1 | 2017 | 1153 | 0.080 |
Why?
| | Brain | 1 | 2020 | 2668 | 0.070 |
Why?
| | Neoplasms | 1 | 2023 | 2671 | 0.070 |
Why?
| | Quality Improvement | 1 | 2016 | 1178 | 0.070 |
Why?
| | Middle Aged | 3 | 2025 | 33479 | 0.070 |
Why?
| | Hypoglycemic Agents | 1 | 2016 | 1291 | 0.070 |
Why?
| | Abnormalities, Multiple | 1 | 2008 | 189 | 0.060 |
Why?
| | Aged | 1 | 2025 | 23961 | 0.060 |
Why?
| | Insulin | 1 | 2016 | 2409 | 0.060 |
Why?
| | Syndrome | 2 | 2020 | 358 | 0.060 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2019 | 2531 | 0.060 |
Why?
| | Sexual Development | 1 | 2023 | 18 | 0.050 |
Why?
| | Europe | 1 | 2024 | 414 | 0.050 |
Why?
| | Karyotyping | 1 | 2023 | 104 | 0.050 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2024 | 212 | 0.050 |
Why?
| | Practice Guidelines as Topic | 2 | 2024 | 1587 | 0.050 |
Why?
| | Menarche | 1 | 2023 | 60 | 0.050 |
Why?
| | 17-alpha-Hydroxyprogesterone | 1 | 2022 | 3 | 0.050 |
Why?
| | Androstenedione | 1 | 2022 | 11 | 0.050 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2022 | 143 | 0.040 |
Why?
| | Prenatal Diagnosis | 1 | 2022 | 201 | 0.040 |
Why?
| | Administration, Oral | 1 | 2022 | 816 | 0.040 |
Why?
| | Counseling | 1 | 2022 | 391 | 0.040 |
Why?
| | Physicians, Women | 1 | 2020 | 83 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2023 | 15657 | 0.040 |
Why?
| | Suicidal Ideation | 1 | 2024 | 529 | 0.040 |
Why?
| | Gene Expression | 1 | 2023 | 1502 | 0.040 |
Why?
| | Genetic Testing | 1 | 2021 | 460 | 0.040 |
Why?
| | Peer Group | 1 | 2020 | 242 | 0.040 |
Why?
| | Minority Groups | 1 | 2020 | 266 | 0.040 |
Why?
| | Career Choice | 1 | 2020 | 219 | 0.040 |
Why?
| | Health Status | 1 | 2023 | 792 | 0.040 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2014 | 3715 | 0.030 |
Why?
| | Universities | 1 | 2020 | 433 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2022 | 2057 | 0.030 |
Why?
| | Social Media | 1 | 2020 | 158 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2021 | 1483 | 0.030 |
Why?
| | Disability Evaluation | 1 | 2018 | 290 | 0.030 |
Why?
| | Suicide | 1 | 2024 | 656 | 0.030 |
Why?
| | Incidence | 1 | 2023 | 2804 | 0.030 |
Why?
| | Occupational Exposure | 1 | 2020 | 341 | 0.030 |
Why?
| | Mental Health | 1 | 2023 | 726 | 0.030 |
Why?
| | Social Support | 1 | 2020 | 618 | 0.030 |
Why?
| | Societies, Medical | 1 | 2020 | 820 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2016 | 160 | 0.030 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 373 | 0.030 |
Why?
| | Patient Participation | 1 | 2019 | 420 | 0.030 |
Why?
| | Coronavirus Infections | 1 | 2020 | 364 | 0.030 |
Why?
| | Interpersonal Relations | 1 | 2017 | 397 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2016 | 508 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 2017 | 1023 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1639 | 0.020 |
Why?
| | Physicians | 1 | 2020 | 910 | 0.020 |
Why?
| | Parents | 1 | 2019 | 1347 | 0.020 |
Why?
| | Pregnancy | 1 | 2022 | 6763 | 0.020 |
Why?
| | Anxiety | 1 | 2017 | 1035 | 0.020 |
Why?
| | Depression | 1 | 2017 | 1397 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 5778 | 0.020 |
Why?
|
|
Davis's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|